R&D

Old drug offers new hope for children with devastating disorder

A drug that once helped obese adults lose weight, but was withdrawn from the market due to heart risks, may be safe and effective for children with a life-threatening seizure disorder called Dravet syndrome, say researchers from UCSF Benioff Children's Hospitals and other major treatment centers.

Filtered coffee helps prevent type 2 diabetes, show biomarkers in blood samples

Coffee can help reduce the risk of developing type 2 diabetes - but only filtered coffee, rather than boiled coffee. New research from Chalmers University of Technology and Umeå University, both in Sweden, show that the choice of preparation method influences the health effects of coffee.

Free tool simplifies cancer research

Every cell contains a vast number of proteins, each of which has a specific function, for example as a receptor for another molecule or an enzyme that catalyses chemical reactions. Disorders of such mechanisms can seriously affect a cell and cause diseases such as cancer, in which the sick cell functions in a fundamentally different way to a healthy cell.

A vaccine against chronic inflammatory diseases

Chronic inflammatory bowel diseases, such as Crohn's Disease and ulcerative colitis, are linked to abnormalities of the gut microbiota in humans and in animals. Patients generally present reduced bacterial diversity in their intestinal flora along with excessive levels of bacteria that express a protein called flagellin, which favors their mobility.

Microcapsules for targeted drug delivery to cancer cells

A team of scientists from Peter the Great St.Petersburg Polytechnic University (SPbPU) together with their colleagues developed a method of targeted drug delivery to cancer cells. The discovery is based on the use of mesenchymal stem cells and microcapsules made of polymeric compounds.

Leukemia, lymphoma squarely in sights of new class of drugs

UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine reported the findings Dec. 2.

Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer

A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows. The phase II trial found that over 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA genes responded well to treatment with the targeted drug olaparib.

Research & Development

Old drug offers new hope for children with devastating disorder

Filtered coffee helps prevent type 2 diabetes, show biomarkers in blood samples

Free tool simplifies cancer research

A vaccine against chronic inflammatory diseases

Microcapsules for targeted drug delivery to cancer cells

Leukemia, lymphoma squarely in sights of new class of drugs

Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer

More Pharma News ...